Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.

ABSTRACT:

Importance

The factors associated with long-term serum levels of anti-SARS-CoV-2 antibodies after COVID-19 vaccination in healthy individuals have rarely been investigated.

Objective

To investigate factors associated with anti-SARS-CoV-2 antibody levels.

Design, setting, and participants

This prospective cohort study included health care workers at Kyungpook National University Chilgok Hospital (Daegu, Korea) with no history of SARS-CoV-2 infection who received 2 doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech; first dose, March 17-20, 2021; second dose, April 7-10, 2021). Serum samples were collected at 2, 4, and 6 months after the second injection.

Interventions

SARS-CoV-2 BNT162b2 mRNA vaccine.

Main outcomes and measures

Anti-SARS-CoV-2 s

SUBMITTER: Nam SY 

PROVIDER: S-EPMC9121186 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature